PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines. METHODS: Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values. These data were analyzed against baseline gene expression data to identify genes associated with PD 0332991 response. RESULTS: Cell lines representing luminal estrogen receptor-positive (ER+) subtype (including those that are HER2 amplified) were most sensitive to growth inhibition by PD 0332991 while nonluminal/basal subtypes were most resistant. Analysis of variance identified 450 differentially expressed genes between sensitive and resistant cells. pRb and cyclin D1 were elevated and CDKN2A (p16) was decreased in the most sensitive lines. Cell cycle analysis showed G0/G1 arrest in sensitive cell lines and Western blot analysis demonstrated that Rb phosphorylation is blocked in sensitive lines but not resistant lines. PD 0332991 was synergistic with tamoxifen and trastuzumab in ER+ and HER2-amplified cell lines, respectively. PD 0332991 enhanced sensitivity to tamoxifen in cell lines with conditioned resistance to ER blockade. CONCLUSIONS: These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In some of these models, resistance can be overcome by including CDK4/6 inhibitors in the treatment (Finn et al., 2009; Goel et al., 2016; Kwong et al., 2012; Vora et al., 2014; Zhou et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2009
In the citing paper
“Preclinical data utilizing palbociclib demonstrated the substantial sensitivity of hormone receptor (HR)-positive cell lines, compared to HR-negative cell lines, in part related to a higher incidence of RB-negativity in the latter breast cancer subgroup (81).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab has been shown to have clinical activity in HER2amplified breast cancer [34].”
BackgroundSelf-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Multiple drug effect analysis was performed using computer software as previously described [33].”
MethodA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“PD 0332991 is an orally active potent and highly selective inhibitor of CDK4 and CDK6 kinases, which in low nanomolar concentrations blocks pRb phosphorylation - subsequently inducing G1 arrest in sensitive cell lines [26-29].”
Background
Research works printed but not linked: 1
- Duchnowska RJJ Thorat MA Morimiya A Sledge GW Li L Biernat W Szczylik C Steeg PS Badve SS Gene expression analysis for prediciton of early brain metastasis in HER2-positive breast cancer patients [abstract 1019] J Clin Oncol 2008 26 20 Suppl abstract 1019
Cited by
Items 401–500 of 1,000
CDK4/6 inhibition is more active against the glioblastoma proneural subtype
Li, M., Xiao, A., Floyd, D. H., Olmez, I., Lee, J., Godlewski, J. A., Bronisz, A., Bhat, K., Sulman, E. P., Nakano, I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19429 · Cited by 59
Foidart, P., Yip, C., Radermacher, J., Blacher, S., Liénard, M., Montero‐Ruiz, L., Maquoi, E., Montaudon, É., Château‐Joubert, S., Collignon, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1880 · Cited by 61
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers
Pesch, A. M., Hirsh, N. H., Chandler, B. C., Michmerhuizen, A. R., Ritter, C. L., Androsiglio, M. P., Wilder-Romans, K., Liu, M., Gersch, C. L., Larios, J. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2269 · Cited by 57
G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis
Billard, M. J., Fitzhugh, D. J., Parker, J. S., Brozowski, J. M., McGinnis, M. W., Timoshchenko, R. G., Serafín, D., Lininger, R. A., Klauber‐DeMore, N., Sahagian, G. G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152856 · Cited by 54
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
Kim, E., & Scott, L. J. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0492-7 · Cited by 53
Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer
Boonyaratanakornkit, V., Hamilton, N. M., Márquez‐Garbán, D. C., Pateetin, P., McGowan, E. M., & Pietras, R. J. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.11.010 · Cited by 56
Steroid Hormone Receptors: Links With Cell Cycle Machinery and Breast Cancer Progression
Saha, S., Dey, S., & Nath, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620214 · Cited by 60
Finn, R. S., Aleshin, A. A., Dering, J., Yang, P. C., Ginther, C., Desai, A. J., Zhao, D., von Euw, E., Busuttil, R. W., & Slamon, D. J. (2013) · Hepatology · doi:10.1002/hep.26223 · Cited by 67
AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
Rejeski, K., Duque‐Afonso, J., & Lübbert, M. (2021) · Oncogene · doi:10.1038/s41388-021-01952-w · Cited by 60
Tapia, M., Hernándo, C., Martínez, M. T., Burgués, O., Tebar, C., Lameirinhas, A., Ágreda‐Roca, A., Torres‐Ruiz, S., Garrido‐Cano, I., Lluch, A. M., et al. (2023) · Cancers · doi:10.3390/cancers15184522 · Cited by 60
Sun, W., O'Dwyer, P. J., Finn, R. S., Ruiz-García, A., Shapiro, G. I., Schwartz, G. K., DeMichele, A. M., & Wang, D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.902 · Cited by 50
Nagaraj, G., & Ma, C. X. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01552-2 · Cited by 53
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
Susanti, N. M. P., & Tjahjono, D. H. (2021) · Molecules · doi:10.3390/molecules26154462 · Cited by 54
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
Wander, S. A., O’Brien, N. A., Litchfield, L. M., O’Dea, D., Guimaraes, C. M., Slamon, D. J., & Goel, S. (2022) · The Oncologist · doi:10.1093/oncolo/oyac138 · Cited by 54
CDK4/6 inhibitors in breast cancer
Dukelow, T., Kishan, D., Khasraw, M., & Murphy, C. G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000249 · Cited by 54
Lou, X., Zhang, J., Liu, S., Lou, X., & Liao, D. J. (2014) · Cell Cycle · doi:10.4161/cc.29082 · Cited by 51
Patel, P. M., Asbach, B., Shteyn, E., Gomez, C., Coltoff, A. R., Bhuyan, S., Tyner, A. L., Wagner, R., & Blain, S. W. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01206-14 · Cited by 57
Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer
Patani, N., & Martin, L. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.09.038 · Cited by 56
CDK4/6 inhibitors in HER2-positive breast cancer
Corona, S. P., Ravelli, A., Cretella, D., Cappelletti, M. R., Zanotti, L., Dester, M., Gobbi, A., Petronini, P. G., & Generali, D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.022 · Cited by 53
Cortés, J., Im, S., Holgado, E., Pérez-García, J. M., Schmid, P., & Chávez‐MacGregor, M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.011 · Cited by 52
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Clark, A. S., McAndrew, N. P., Troxel, A. B., Feldman, M. D., Lal, P., Rosen, M. A., Burrell, J. A., Redlinger, C., Gallagher, M., Bradbury, A. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0790 · Cited by 49
Pyridines and their Benzo Derivatives: Applications
McAteer, C. H., Balasubramanian, M., & Murugan, R. (2008) · Elsevier eBooks · doi:10.1016/b978-008044992-0.00606-4 · Cited by 53
Pavlovic, D., Nićiforović, D., Papic, D., Milojevic, K., & Marković, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231205848 · Cited by 58
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Metzger, O., Mandrekar, S. J., Goel, S., Gligorov, J., Lim, E., Ciruelos, E., Loibl, S., Dockter, T., González, X., Francis, P. A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2511218 · Cited by 62
Suh, K. S., Sarojini, S., Youssif, M., Nalley, K., Milinovikj, N., Elloumi, F., Russell, S., Pecora, A. L., Schecter, E., & Goy, A. H. (2013) · Journal of Oncology · doi:10.1155/2013/368751 · Cited by 54
Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
Başaran, G., Twelves, C. J., Dieras, V. C., Cortés, J., & Awada, A. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.002 · Cited by 51
Preusser, M., Mattos‐Arruda, L. D., Thill, M., Criscitiello, C., Bartsch, R., Ruhstaller, T., de Azambuja, E., & Zielinski, C. C. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000368 · Cited by 49
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 55
Measuring and Modelling the Epithelial- Mesenchymal Hybrid State in Cancer: Clinical Implications
Jolly, M. K., Murphy, R. J., Bhatia, S., Whitfield, H. J., Redfern, A. D., Davis, M. J., & Thompson, E. W. (2021) · Cells Tissues Organs · doi:10.1159/000515289 · Cited by 51
Li, X., Li, J., Xu, L., Wei, W., Cheng, A., Zhang, L., Zhang, M., Wu, G., & Cai, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02362-w · Cited by 59
Mangini, N. S., Wesolowski, R., Ramaswamy, B., Lustberg, M. B., & Berger, M. J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015602273 · Cited by 55
Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines
Matutino, A. R. B., Joy, A. A., Brezden‐Masley, C., Chia, S., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.4000 · Cited by 56
Gul, A., Leyland-Jones, B., Dey, N., & De, P. K. (2018) · Europe PMC (PubMed Central) · Cited by 48
Retinoblastoma protein expression and its predictors in triple-negative breast cancer
Patel, J. M., Goss, A. J., Garber, J. E., Torous, V. F., Richardson, E. T., Haviland, M. J., Hacker, M. R., Freeman, G. J., Nalven, T., Alexander, B. M., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0160-4 · Cited by 52
Dehdashti, F., Wu, N., Ma, C. X., Naughton, M. J., Katzenellenbogen, J. A., & Siegel, B. A. (2021) · Nature Communications · doi:10.1038/s41467-020-20814-9 · Cited by 47
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
Agostinetto, E., Eiger, D., Punie, K., & de Azambuja, E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01038-6 · Cited by 48
Lu, J., McEachern, D., Li, S., Ellis, M. J., & Wang, S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0028 · Cited by 46
miR-221/222 control luminal breast cancer tumor progression by regulating different targets
Dentelli, P., Traversa, M., Rosso, A., Togliatto, G., Olgasi, C., Marchiò, C., Provero, P., Lembo, A., Bon, G., Annaratone, L., et al. (2014) · Cell Cycle · doi:10.4161/cc.28758 · Cited by 51
PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
Abraham, J. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.961429 · Cited by 46
Gremel, G., Liew-Littorin, M., Hamzei, F., Hardell, E., Selling, J., Ghaderi, M., Stemme, S., Pontén, F., & Carlson, J. W. (2014) · International Journal of Cancer · doi:10.1002/ijc.29141 · Cited by 47
Węsierska‐Gądek, J., Gritsch, D., Zulehner, N., Komina, O., & Maurer‐Granofszky, M. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23004 · Cited by 49
Lim, S. M., Kim, E. Y., Kim, H. R., Ali, S. M., Greenbowe, J. R., Shim, H. S., Chang, H. K., Lim, S., Paik, S., & Cho, B. C. (2016) · Oncotarget · doi:10.18632/oncotarget.8138 · Cited by 52
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
Augereau, P., Patsouris, A., Bourbouloux, E., Gourmelon, C., Lacourtoisie, S. A., Rigaud, D. B., Soulié, P., Frenel, J., & Campone, M. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017693195 · Cited by 50
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
Liu, C., Wu, C., Petrossian, K., Huang, T., Tseng, L., & Chen, S. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.07.001 · Cited by 55
Durairaj, C., Ruiz-García, A., Gauthier, E. R., Huang, X., Lu, D. R., Hoffman, J., Finn, R. S., Joy, A. A., Ettl, J., Rugo, H. S., et al. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000589 · Cited by 48
Fasching, P. A., Gaß, P., Häberle, L., Volz, B., Hein, A., Hack, C. C., Lux, M. P., Jud, S. M., Hartmann, A., Beckmann, M. W., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05198-9 · Cited by 52
Intrinsic molecular subtypes of HER2+ breast cancer
Prat, A., Pascual, T., & Adamo, B. (2017) · Oncotarget · doi:10.18632/oncotarget.20629 · Cited by 46
Kalbasi, A. K., Fonsatti, E., Natali, P. G., Altomonte, M., Bertocci, E., Cutaia, O., Calabrò, L., Chiou, M., Tap, W. D., Chmielowski, B., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee73a7 · Cited by 47
Yu, Z., Zhan, C., Du, H., Zhang, L., Liang, C., & Zhang, L. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03739-1 · Cited by 48
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 57
Martín‐Broto, J., Martínez-García, J., Moura, D. S., Redondo, A., Gutierrez, A. M., Pousa, A. L., Martínez‐Trufero, J., Sevilla, I., Diaz-Beveridge, R., Solís-Hernández, M. P., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01661-8 · Cited by 52
Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions
Jurić, V., & Murphy, B. M. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.105 · Cited by 56
Soria‐Bretones, I., Thu, K. L., Silvester, J., Cruickshank, J., Ghamrasni, S. E., Ba-Alawi, W., Fletcher, G. C., Kiarash, R., Elliott, M. J., Chalmers, J. J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq4293 · Cited by 52
Maskey, R. S., Wang, F., Lehman, E., Wang, Y., Emmanuel, N., Zhong, W., Jin, G., Abraham, R. T., Arndt, K. T., Myers, J. S., et al. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1859195 · Cited by 51
Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
Gámez-Chiachio, M., Sarrió, D., & Moreno‐Bueno, G. (2022) · Cancers · doi:10.3390/cancers14184543 · Cited by 53
Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Morikawa, A., & Henry, N. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0390 · Cited by 50
Optimizing Endocrine Therapy for Breast Cancer
Zelnak, A. B., & O'Regan, R. M. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0125 · Cited by 48
Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas
Richardson, T. E., Sathe, A. A., Kanchwala, M., Jia, G., Habib, A. A., Xiao, G., Snuderl, M., Xing, C., & Hatanpaa, K. J. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly026 · Cited by 48
Ettl, J., Im, S., Ro, J., Masuda, N., Colleoni, M. A., Schnell, P., Bananis, E., Lu, D. R., Cristofanilli, M., Rugo, H. S., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01263-0 · Cited by 45
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Gomatou, G., Trontzas, I. P., Ioannou, S., Drizou, M., Syrigos, N. K., & Kotteas, E. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06100-3 · Cited by 47
Brufsky, A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.004 · Cited by 50
ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
Reese, J. M., Bruinsma, E. S., Monroe, D. G., Negron, V. C., Suman, V. J., Ingle, J. N., Goetz, M. P., & Hawse, J. R. (2017) · Oncotarget · doi:10.18632/oncotarget.21787 · Cited by 47
Precision Medicine in Hormone Receptor-Positive Breast Cancer
Nasrazadani, A., Thomas, R. A., Oesterreich, S., & Lee, A. V. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00144 · Cited by 51
Feng, W. W., & Kurokawa, M. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.100 · Cited by 49
Tang, S., Sethunath, V., Metaferia, N. Y., Nogueira, M. F., Gallant, D. S., Garner, E. R., Lairson, L. A., Penney, C. M., Li, J., Gelbard, M. K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110417 · Cited by 46
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
Herrera-Abreu, M. T., Guan, J., Khalid, U., Ning, J., Costa, M. R., Chan, J., Li, Q., Fortin, J., Wong, W., Perampalam, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53837-7 · Cited by 55
Hudson, K., Hancox, U. J., Trigwell, C. B., McEwen, R. K., Polanska, U. M., Nikolaou, M., Gutierrez, P. M., Avivar‐Valderas, A., Delpuech, O., Dudley, P., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0687 · Cited by 42
Rocca, A., Maltoni, R., Bravaccini, S., Donati, C., & Andreis, D. (2018) · Cancer Management and Research · doi:10.2147/cmar.s137772 · Cited by 45
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
Zhang, K., Hong, R., Lee, K., Xu, F., Xia, W., Qin, G., Zheng, Q., Lu, Q., Zhai, Q., Shi, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.005 · Cited by 48
The emerging role of CDK4/6i in HER2-positive breast cancer
O'Sullivan, C. C., Suman, V. J., & Goetz, M. P. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919887665 · Cited by 46
Roles of autophagy in breast cancer treatment: Target, bystander or benefactor
Tyutyunyk‐Massey, L., & Gewirtz, D. A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.008 · Cited by 45
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
Mezni, E., Vicier, C., Guérin, M., Sabatier, R., Bertucci, F., & Gonçalvès, A. (2020) · Cancers · doi:10.3390/cancers12061573 · Cited by 46
Nabieva, N., & Fasching, P. A. (2021) · Cancers · doi:10.3390/cancers13225643 · Cited by 46
Katsumi, Y., Iehara, T., Miyachi, M., Yagyu, S., Tsubai-Shimizu, S., Kikuchi, K., Tamura, S., Kuwahara, Y., Tsuchiya, K., Kuroda, H., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.08.047 · Cited by 48
CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
Saleh, L., Wilson, C., & Holen, I. (2021) · MedComm · doi:10.1002/mco2.97 · Cited by 44
Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus
Wan, Q., Tavakoli, L., Wang, T., Tucker, A. J., Zhou, R., Liu, Q., Feng, S., Choi, D., He, Z., Gack, M. U., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45852-5 · Cited by 42
Nguyen, L., Zhong, W.-Z., Painter, C. L., Zhang, C., Rahavendran, S. V., & Shen, Z. (2010) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2010.02.031 · Cited by 41
Alinari, L., Prince, C. J., Edwards, R. B., Towns, W. H., Mani, R., Lehman, A., Zhang, X., Jarjoura, D. G., Pan, L., Kinghorn, A. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0839 · Cited by 48
Perez, E. A. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.001 · Cited by 43
Dange, Y. D., Bhinge, S. D., & Salunkhe, V. R. (2017) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2017.1388458 · Cited by 46
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
Green, J. L., Okerberg, E. S., Sejd, J. R., Palafox, M., Monserrat, L., Alemayehu, S., Wu, J., Sykes, M., Aban, A., Serra, V., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0755 · Cited by 43
Grande, E., Teulé, À., Alonso‐Gordoa, T., Jiménez‐Fonseca, P., Benavent, M., Capdevila, J., Custodio, A., Vera, R., Munárriz, J., Casta, A. L., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0033 · Cited by 44
CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck
Billard-Sandu, C., Tao, Y., Sablin, M., Dumitrescu, G., Billard, D., & Deutsch, É. (2020) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-020-05891-2 · Cited by 45
Goldstein, M. J., Peters, M., Weber, B. L., & Davis, C. B. (2020) · Clinical and Translational Science · doi:10.1111/cts.12902 · Cited by 47
Rana, S., Mallareddy, J. R., Singh, S., Boghean, L., & Natarajan, A. (2021) · Cancers · doi:10.3390/cancers13215506 · Cited by 46
Abu-Khalaf, M. M., Hodge, K. A., Hatzis, C., Baldelli, E., Gazzah, E. E., Valdes, F., Sikov, W. M., Mita, M. M., Denduluri, N., Murphy, R., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00360-5 · Cited by 50
Stanciu, I.-M., Paroșanu, A. I., & Niţipir, C. (2023) · Biomolecules · doi:10.3390/biom13091422 · Cited by 48
Sultan, R., Ahmed, A., Li, W., Saeed, H., Islam, M. F., & Ishaq, M. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04198-z · Cited by 46
Cyclin-dependent kinase pathways as targets for women's cancer treatment
Konecny, G. E. (2015) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000243 · Cited by 46
Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb
Egger, J. V., Lane, M. V., Antonucci, L., Dedi, B., & Krucher, N. A. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1235668 · Cited by 39
ETS‐targeted therapy: can it substitute for MEK inhibitors?
Tetsu, O., & McCormick, F. P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0147-4 · Cited by 45
Shohdy, K. S., Lasheen, S., Kassem, L. M. H., & Abdel-Rahman, O. M. (2017) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617722516 · Cited by 39
Profile of abemaciclib and its potential in the treatment of breast cancer
Martin, J., & Goldstein, L. J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s149245 · Cited by 42
Lin, Z., Zhang, X., Zhao, F., & Ru, S. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.01.017 · Cited by 50
Role for polo-like kinase 4 in mediation of cytokinesis
Press, M. F., Xie, B., Davenport, S., Zhou, Y., Guzman, R., Nolan, G. P., O’Brien, N. A., Palazzolo, M., Mak, T. W., Brugge, J. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818820116 · Cited by 41
Xi, J., & Ma, C. X. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00917-8 · Cited by 47
Bardia, A., Su, F., Solovieff, N., Im, S., Sohn, J., Lee, K. S., Campos-Gómez, S., Jung, K. H., Colleoni, M. A., Villanueva-Vázquez, R., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00445 · Cited by 44
Rätze, M. A. K., Koorman, T., Sijnesael, T., Bassey-Archibong, B. I., van de Ven, R., Enserink, L. N. F. L., Visser, D., Jaksani, S., Viciano, I., Bakker, E. R. M., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02314-w · Cited by 39
Anwer, M. K., Fatima, F., Ahmed, M. M., Aldawsari, M. F., Alali, A. S., Kalam, M. A., Alshamsan, A., Alkholief, M. A., Malik, A., Alanazi, A. Z., et al. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.03.019 · Cited by 45
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
Hagen, K. R., Zeng, X., Lee, M.-Y., Kahn, S., Pitner, M. K., Zaky, S. S., Liu, Y., O’Regan, R. M., Deng, X., & Saavedra, H. I. (2013) · Cell Division · doi:10.1186/1747-1028-8-10 · Cited by 42
Metadata
- Authors
- Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., Los, G., & Slamon, D. J.
- Affiliations
- University of California, Los Angeles (US)
- Pfizer (United States) (US)
- Corresponding author
- Finn, Richard S
- Venue
- Breast Cancer Research
- Published
- 2009-10-29
- Volume
- 11
- Issue
- 5
- Pages
- R77-R77
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- PMC
- PMC2790859
- OpenAlex
- W2148345265
- Cited by
- 1,398
- References
- 49
- Citations by year
- 2026: 48 · 2025: 76 · 2024: 64 · 2023: 94 · 2022: 115 · 2021: 121 · 2020: 137 · 2019: 128 · 2018: 137 · 2017: 131 · 2016: 105 · 2015: 92 · 2014: 51 · 2013: 42 · 2012: 28
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Breast Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH)
- Russian Science Foundation
- National Institutes of Health (W81XWH)
- Jonsson Comprehensive Cancer Center
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- palbociclib, CDK4/6 inhibitors, HER2-amplified breast cancer, retinoblastoma protein phosphorylation, cyclin D1, CDKN2A, p16, G0/G1 cell cycle arrest, drug sensitivity, drug resistance, patient selection, breast cancer cell lines
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cell Cycle, Drug Synergism, Humans, Phosphorylation, Piperazines, Pyridines, Receptors, Estrogen, Tamoxifen, Retinoblastoma Protein, Apoptosis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Gene Expression Profiling, Cell Line, Tumor, Cell Growth Processes, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.